Marek Minárik

2.0k total citations
97 papers, 1.4k citations indexed

About

Marek Minárik is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Marek Minárik has authored 97 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Marek Minárik's work include Lung Cancer Treatments and Mutations (34 papers), Cancer Genomics and Diagnostics (19 papers) and Colorectal Cancer Treatments and Studies (19 papers). Marek Minárik is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Cancer Genomics and Diagnostics (19 papers) and Colorectal Cancer Treatments and Studies (19 papers). Marek Minárik collaborates with scholars based in Czechia, Slovakia and United States. Marek Minárik's co-authors include Lucie Benešová, Miloš Pešek, Ondřej Fiala, František Foret, Barbora Belšánová, Jindřich Fínek, Zbyněk Bortlíček, Barry L. Karger, Ondřej Topolčan and Per Olaf Ekstrøm and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Marek Minárik

93 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marek Minárik Czechia 25 570 532 453 379 262 97 1.4k
Isabelle Valo France 16 381 0.7× 462 0.9× 311 0.7× 211 0.6× 50 0.2× 34 1.0k
Witold Rzyman Poland 25 595 1.0× 1.0k 1.9× 629 1.4× 436 1.2× 54 0.2× 110 1.8k
C. Sturgeon United Kingdom 13 916 1.6× 341 0.6× 473 1.0× 323 0.9× 62 0.2× 28 1.6k
Bonnie L. Kemp United States 24 765 1.3× 709 1.3× 994 2.2× 558 1.5× 152 0.6× 38 2.5k
Dawid Murawa Poland 19 536 0.9× 402 0.8× 259 0.6× 434 1.1× 296 1.1× 113 1.7k
Yoshifumi Morita Japan 16 257 0.5× 268 0.5× 406 0.9× 279 0.7× 86 0.3× 83 1.1k
Kinji Kamiya Japan 24 393 0.7× 480 0.9× 354 0.8× 262 0.7× 79 0.3× 78 1.3k
R Klapdor Germany 15 774 1.4× 232 0.4× 403 0.9× 225 0.6× 52 0.2× 78 1.4k
Cédric Poyet Switzerland 20 311 0.5× 751 1.4× 394 0.9× 221 0.6× 75 0.3× 121 1.5k
Axel Hegele Germany 23 409 0.7× 709 1.3× 600 1.3× 246 0.6× 67 0.3× 134 1.9k

Countries citing papers authored by Marek Minárik

Since Specialization
Citations

This map shows the geographic impact of Marek Minárik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Minárik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Minárik more than expected).

Fields of papers citing papers by Marek Minárik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Minárik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Minárik. The network helps show where Marek Minárik may publish in the future.

Co-authorship network of co-authors of Marek Minárik

This figure shows the co-authorship network connecting the top 25 collaborators of Marek Minárik. A scholar is included among the top collaborators of Marek Minárik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marek Minárik. Marek Minárik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Řemínek, Roman, et al.. (2024). 3D-printed device for time- and cost-efficient sample preparation and DNA fractionation. Talanta. 286. 127461–127461. 1 indexed citations
2.
Minárik, Marek, et al.. (2018). Activity of Skin Cancer Clinic at Martin University Hospital in 2017. SHILAP Revista de lepidopterología. 18(1). 21–29. 1 indexed citations
3.
Fiala, Ondřej, Petr Hošek, Miloš Pešek, et al.. (2017). Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC. Anticancer Research. 37(11). 6469–6476. 13 indexed citations
4.
Minárik, Marek, Lucie Benešová, Tereza Hálková, et al.. (2016). IDH1/2 Mutation and MGMT Promoter Methylation – the Relevant Survival Predictors in Czech Patients with Brain Gliomas. Folia Biologica. 62(5). 194–202. 11 indexed citations
5.
Minárik, Marek. (2016). Molecular profiling of lung cancer. 10(1). 7–10. 7 indexed citations
6.
Kohoutová, Darina, Miroslav Podhola, Stanislav Rejchrt, et al.. (2016). The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature. Gastrointestinal Endoscopy. 84(4). 718–725. 51 indexed citations
7.
Benešová, Lucie, Barbora Belšánová, Miroslav Levý, et al.. (2016). Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery. Advances in Clinical and Experimental Medicine. 25(6). 1273–1279. 7 indexed citations
8.
Fiala, Ondřej, Miloš Pešek, Jindřich Fínek, et al.. (2015). Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumor Biology. 36(8). 5801–5805. 30 indexed citations
9.
Jurko, A, et al.. (2013). Left ventricular systolic and diastolic function in children with overweight and obesity. Bratislavské lekárske listy/Bratislava medical journal. 114(9). 526–530. 5 indexed citations
10.
Fiala, Ondřej, Miloš Pešek, Jindřich Fínek, et al.. (2013). Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC. Neoplasma. 60(4). 425–431. 11 indexed citations
11.
Benešová, Lucie, Barbora Belšánová, Štěpán Suchánek, et al.. (2012). Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Analytical Biochemistry. 433(2). 227–234. 89 indexed citations
12.
Fiala, Ondřej, Miloš Pešek, Jindřich Fínek, et al.. (2012). Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice. Neoplasma. 60(1). 26–32. 18 indexed citations
13.
Jurko, A & Marek Minárik. (2011). Doppler-derived myocardial performance index in healthy children.. PubMed. 112(2). 77–9. 7 indexed citations
14.
Pešek, Miloš, et al.. (2009). Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.. PubMed. 29(7). 2767–73. 33 indexed citations
15.
Roewer, Lutz, et al.. (2009). Assembly of a large Y-STR haplotype database for the Czech population and investigation of its substructure. Forensic Science International Genetics. 4(3). e75–e78. 14 indexed citations
16.
Minárik, Marek, et al.. (2004). The outcome of patients with severe head injuries treated with amantadine sulphate. Journal of Neural Transmission. 111(4). 511–514. 52 indexed citations
17.
Minárik, Marek, František Foret, & Barry L. Karger. (2000). Fraction collection in micropreparative capillary zone electrophoresis and capillary isoelectric focusing. Electrophoresis. 21(1). 247–254. 53 indexed citations
18.
19.
Bánovčin, Peter, et al.. (1992). [Broncho-Vax and IRS 19 in the treatment of recurrent respiratory tract inflammation in children].. PubMed. 47(11). 666–9. 2 indexed citations
20.
Javorka, K, et al.. (1988). Heart Rate and its Variability in Juvenile Hypertonics During Respiratory Maneuvers. Clinical and Experimental Hypertension Part A Theory and Practice. 10(3). 391–409. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabelle Valo Breakdown of academic impact, for papers by Witold Rzyman Breakdown of academic impact, for papers by C. Sturgeon Breakdown of academic impact, for papers by Bonnie L. Kemp Breakdown of academic impact, for papers by Dawid Murawa Breakdown of academic impact, for papers by Yoshifumi Morita Breakdown of academic impact, for papers by Kinji Kamiya Breakdown of academic impact, for papers by R Klapdor Breakdown of academic impact, for papers by Cédric Poyet Breakdown of academic impact, for papers by Axel Hegele
Rankless by CCL
2026